NorthWest Biotherapeutics Inc (NWBO)

[Margin Buu]

You need to look at the data in context to understand why DCVax is a big deal.

Newly diagnosed patients given DCVax, survived for an average of 19.3 months compared with 16.5 months for those taking a placebo.

Patients whose GBM had recurred survived on average for 13.2 months on DCVax compared with just 7.8 months for those not given the vaccine.

While only 5.7% of the control group survived 5 years, 13% of people receiving DCVax survived 5 years.

DCVax-L more than doubles patients chances of surviving 5 years (or greater?) compared to the SOC. Sounds good to me.

DCVax Brain cancer vaccine trial concludes successfully